Previous 10 | Next 10 |
Patients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieved at week 24 on aflibercept alone, with greater vision improvement in patients with more severe disease Patients with prior anti-VEGF treatment and switched to UBX1325 monother...
2023-08-08 17:28:31 ET Unity Biotechnology press release ( NASDAQ: UBX ): Q2 GAAP EPS of -$0.85 in-line. Cash, cash equivalents and marketable securities totaled $71.0 million as of June 30, 2023 compared with $94.8 million as of December 31, 2022. UNITY believes that ...
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2023. “We...
Phase 2b trial is a randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 (foselutoclax) compared to aflibercept over 24 weeks First novel senolytic therapeutic candidate to be evaluated head-to-head against standard of care anti-...
2023-05-09 17:43:10 ET Unity Biotechnology press release ( NASDAQ: UBX ): Q1 GAAP EPS of -$0.76. Cash, cash equivalents and marketable securities totaled $83.4 million as of March 31, 2023 compared with $94.8 million as of December 31, 2022. UNITY believes that current cas...
SOUTH SAN FRANCISCO, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2023. “The...
A single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in Best Corrected Visual Acuity ( BCVA) of +6.2 ETDRS letters from baseline at 48 weeks Approximately 53% of UBX1325-treated patients did not require any additional injecti...
2023-04-17 13:18:04 ET Gainers: Presto Automation ( PRST ) +183% . Windtree Therapeutics ( WINT ) +175% . Blackboxstocks ( BLBX ) +125% . Prometheus Biosciences ( RXDX ) +69% . Peakstone Realty Trust ( PKST ) +46% . Dragonfly...
2023-04-11 16:25:47 ET Unity Biotechnology ( NASDAQ: UBX ) said its chief medical officer Jamie Dananberg would leave the company, effective April 30. The company said Dananberg would receive a severance payment equal to nine months of his base salary and continued ...
2023-03-27 13:06:40 ET Gainers: WiSA Technologies ( WISA ) +93% . First Citizens BancShares ( FCNCA ) +50% . Alimera Sciences ( ALIM ) +38% . Cimpress ( CMPR ) +30% . Gorilla Technology Group ( GRRR ) +25% . CBL International...
News, Short Squeeze, Breakout and More Instantly...
Unity Biotechnology Inc. Company Name:
UBX Stock Symbol:
NASDAQ Market:
Unity Biotechnology Inc. Website:
SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2024. "Our team r...
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company develo...
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company will present two poster presentations at t...